Sartorius Stedim BiotechCHIX:DIMP 84 EBITDA Margin % is 32.40% as of Mar. 2026, which is 18% above its 10-year median of 27.56. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €207.88 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks better than 87.87% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sartorius Stedim Biotech EBITDA Margin % Related Terms
Sartorius Stedim Biotech EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a EBITDA Margin % of 32.40% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sartorius Stedim Biotech and its competitors. This is 18% above median its historical median of 27.56. Over the past decade, Sartorius Stedim Biotech's EBITDA Margin % has ranged from 24.12 to 38.10. According to the industry distribution chart, Sartorius Stedim Biotech ranks #99 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 12.1%.
Is Sartorius Stedim Biotech's EBITDA Margin % too high?
Sartorius Stedim Biotech's current EBITDA Margin % of 32.40% is 18% above median its 10-year median of 27.56. Over the past 10 years, this metric has ranged from a low of 24.12 to a high of 38.10. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Sartorius Stedim Biotech's value of 32.40% is 333.4% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #99 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #99 out of 816 companies for EBITDA Margin %. This places Sartorius Stedim Biotech in the top 12% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Sartorius Stedim Biotech's value of 32.40% is 333.4% above this benchmark. Historically, Sartorius Stedim Biotech's own EBITDA Margin % has ranged from 24.12 to 38.10 over the past decade. While the company's 10-year median is 27.56 vs. the industry median of 7.48, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current EBITDA Margin % of 32.40% is 333.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current EBITDA Margin % is 32.40%, which is 18% above median its own 10-year median of 27.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €207.88, compared to a current price of €162.10 — trading 22% below its estimated fair value. The current EBITDA Margin % is 32.40%, which is 18% above median its 10-year median of 27.56 and 333.4% above the Medical Devices & Instruments industry median of 7.48. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current EBITDA Margin % is 32.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €162.10 is trading 22% below its estimated GF Value™ of €207.88.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
EBITDA Margin %: 32.40% (18% above median its 10-year median of 27.56)
GF Value™: €207.88 vs. price of €162.10 (22% below fair value)
Industry Position: 333.4% above the Medical Devices & Instruments median (#99 of 816)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score
Get the complete analysis for CHIX:DIMP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
